An Air India pilot tested positive for marijuana and sleep medication following a turbulence incident that injured dozens of passengers [1], [2].
The incident raises critical questions about crew health screenings and airline oversight. The discovery of controlled substances in a pilot's bloodstream during an active flight suggests a potential failure in safety protocols designed to prevent impaired operation of aircraft.
The flight departed from Phuket, Thailand, bound for Delhi, India, on Aug. 4, 2024 [2]. During the journey, the aircraft encountered turbulence that caused a sudden loss of altitude of about 300 feet [2]. The abrupt drop resulted in injuries to at least 24 people [2].
There were 137 passengers and eight crew members on board the aircraft [2]. Following the landing in Delhi, investigations revealed that the pilot had marijuana in his bloodstream [1]. Further tests indicated the pilot was also using sleep medication [2].
One passenger said that the pilot seemed high and that his eyes were red [1]. Authorities are now investigating the pilot's fitness to fly to determine if the impairment contributed to the aircraft's instability during the turbulence [1], [2].
Air India has not released a formal statement regarding the pilot's employment status. The investigation remains ongoing as regulators examine whether the combination of marijuana and sleep medication impaired the pilot's reaction time or judgment during the altitude loss [2].
“The pilot tested positive for marijuana and was also on sleep medication.”
This incident highlights a significant vulnerability in aviation safety regarding the monitoring of pilot health and substance use. The simultaneous presence of a psychoactive substance and sleep medication suggests a level of impairment that could severely degrade a pilot's ability to manage emergency situations, such as severe turbulence. It may prompt aviation regulators to implement more rigorous, random drug testing and stricter medical certifications for flight crews.
